Skip to main content

Table 1 Psoriasin expression and clinical/pathological characteristics of lung cancer

From: The clinical significance of Psoriasin for non-small cell lung cancer patients and its biological impact on lung cancer cell functions

Clinical/pathological features

Sample no.

Median (Copy no.)

IQR

P-value

Tumour tissue

83

0.17

0-27.5

 

Background tissue

69

0.01

0-1

0.0195

Paired tumour tissue

61

0.17

0-24.1

 

Paired background tissue

61

0.01

0-1

0.0251

Gender

    

Male

47

   

Female

25

   

Histology

    

Squamous carcinoma

30

0.4

0-45

 

Adenocarcinoma

37

0.1

0-4.1

0.035

Others

6

N/A

N/A

 

TNM staging

    

I

22

0

0-15.3

 

II

16

0.1

0-110.8

0.22

III

34

1

0-43

0.085

Tumour differentiation

    

High

5

0.1

0-27.2

 

Med

33

1

0-42

0.17

Low

11

0.01

0-1.15

0.51

Tumour status

    

T1

8

3.99

0-13.87

 

T2

41

0

0-22.2

0.989

T3

23

25.6

0-225.6

0.081

Lymph node status

    

N0

24

0

0-18

 

N1

13

0.1

0-77.6

0.93

N2

25

1

0-42

0.51

Smoking status

    

Former or current smoker

49

0.2

0-43

 

Non smoker

23

0

0-12

0.0372